Abstract
Autoimmunity affects a substantial fraction of our population. In patients with autoimmune disease, the immune system recognizes self-tissues as foreign. Common autoimmune diseases include rheumatoid arthritis, diabetes mellitus, lupus and multiple sclerosis. Though different target organs may be affected in different autoimmune diseases, aberrations in adaptive or innate immunity underlie all of these diseases. Abnormal functioning, differentiation and/or activation of T-cells, B-cells and myeloid cells have been documented in various autoimmune diseases. More recent studies have also detailed anomalous activation of various signaling axes including various MAPK, AKT, NF-κB, Bcl-2 family members, and JAK/STAT molecules in these cells, in the context of systemic autoimmunity. Among these, one molecular pathway that appears to be particularly attractive for therapeutic targeting is the PI3K/AKT/mTOR axis. In this review, we summarize how the AKT axis affects multiple molecular processes in autoimmune diseases and discuss the potential of targeting this axis in these diseases.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: The AKT Axis as a Therapeutic Target in Autoimmune Diseases
Volume: 9 Issue: 2
Author(s): Tianfu Wu and Chandra Mohan
Affiliation:
Abstract: Autoimmunity affects a substantial fraction of our population. In patients with autoimmune disease, the immune system recognizes self-tissues as foreign. Common autoimmune diseases include rheumatoid arthritis, diabetes mellitus, lupus and multiple sclerosis. Though different target organs may be affected in different autoimmune diseases, aberrations in adaptive or innate immunity underlie all of these diseases. Abnormal functioning, differentiation and/or activation of T-cells, B-cells and myeloid cells have been documented in various autoimmune diseases. More recent studies have also detailed anomalous activation of various signaling axes including various MAPK, AKT, NF-κB, Bcl-2 family members, and JAK/STAT molecules in these cells, in the context of systemic autoimmunity. Among these, one molecular pathway that appears to be particularly attractive for therapeutic targeting is the PI3K/AKT/mTOR axis. In this review, we summarize how the AKT axis affects multiple molecular processes in autoimmune diseases and discuss the potential of targeting this axis in these diseases.
Export Options
About this article
Cite this article as:
Wu Tianfu and Mohan Chandra, The AKT Axis as a Therapeutic Target in Autoimmune Diseases, Endocrine, Metabolic & Immune Disorders - Drug Targets 2009; 9 (2) . https://dx.doi.org/10.2174/187153009788452417
DOI https://dx.doi.org/10.2174/187153009788452417 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antiviral Agents in the Prevention and Treatment of Virus-Induced Diabetes
Anti-Infective Agents in Medicinal Chemistry Resistance Exercise Versus Aerobic Exercise Combined with Metformin Therapy in the Treatment of type 2 Diabetes: A 12-Week Comparative Clinical Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Advanced Glycation End Products and Insulin Resistance
Current Pharmaceutical Design Current Treatment Strategies for Non-Alcoholic Fatty Liver Disease (NAFLD)
Current Drug Discovery Technologies Appropriate Application of Evidence to the Care of Elderly Patients with Diabetes
Current Diabetes Reviews Pharmacological Modulation of Microparticle Release: New Strategies for the Management of Atherothrombotic Vascular Disorders
Current Pharmaceutical Design Clinical Studies with Paclitaxel - Eluting Stent Systems
Current Pharmaceutical Design Management of Acute and Chronic Open Wounds: The Importance of Moist Environment in Optimal Wound Healing
Current Pharmaceutical Biotechnology Epidural Steroid Injections Do Not Induce Weight Gain
Current Drug Safety Bone Effects of Glitazones and Other Anti-Diabetic Drugs
Current Drug Safety Microparticles: From Biogenesis to Biomarkers and Diagnostic Tools in Cardiovascular Disease
Current Stem Cell Research & Therapy Caffeic Acid Phenethyl Ester Restores Adipocyte Gene Profile Expression Following Lipopolysaccharide Treatment
Letters in Drug Design & Discovery Apoptosis: A Key in Neurodegenerative Disorders
Current Neurovascular Research Withdrawn: Diabetes Mellitus Prognosis Using Fuzzy Logic and Neural Networks Case Study: Alexandria Vascular Center (AVC)
Recent Advances in Computer Science and Communications Podocytes as a Target of Insulin
Current Diabetes Reviews Molecular Characteristics of Autoimmune Pancreatitis
Current Pharmaceutical Design Sorbitol Dehydrogenase: Structure, Function and Ligand Design
Current Medicinal Chemistry Adipose Tissue as a Regulator of Energy Balance
Current Drug Targets Role of Polyphenols in Diet and Nutrition-An Updated Review
Current Nutrition & Food Science Epigenetic Mechanisms and Kidney Diseases
Current Medicinal Chemistry